Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants

3 Jun 2025

Abstract excerpt

SARS-CoV-2 continues to evolve and evade vaccine immunity necessitating vaccines that offer broad protection across variants. Conventional mRNA vaccines face cost and scalability challenges, prompting the exploration of alternative platforms like trans-amplifying (TA) mRNA that offer advantages in safety, manufacturability, and antigen dose optimization. Using consensus sequence of immunodominant antigens is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40461576
DOI: 10.1038/s41541-025-01166-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variantsPMID 40461576Read ↗

Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal modelsSemantic proximity Read ↗

Structure-guided design of a bivalent SARS-CoV-2 mRNA vaccine with NTD stabilizing mutations enhances broad immunity.Semantic proximity Read ↗

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studiesSemantic proximity Read ↗

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessSemantic proximity Read ↗

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strainsSemantic proximity Read ↗

A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical modelsSemantic proximity Read ↗

Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2Semantic proximity Read ↗

Wobble Vaccines: Complex Vaccine Antigen Pools Promote Increased Antibody Breadth and Cross-Strain Viral Targeting in SARS-CoV-2Semantic proximity Read ↗

Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccinesSemantic proximity Read ↗

Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccinationSemantic proximity Read ↗

mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognitionSemantic proximity Read ↗

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strainsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.